Friday, November 2, 2018

DNAe Aims At Treating Antimicrobial Resistant Infections

Carlsbad-based DNAe says it has developed a new, diagnostic platform that uses semiconductor DMA to help in treating antimicrobial resistant infections. According to the company, it completed the first phase of a $51.9M million contract with the U.S. government to developing DNA sequencing technology to help physicians by providing rapid diagnosis of antimicrobial resistant infections and influenza. The U.S. contract was awarded in 2016 by the Biomedical Advanced Research and Development Authority (BARDA). Although the product is not yet available on the market, DNAe says it has developed technology which successfully sequences DNA of bacteria from an unprocessed blood sample, which ultimately will enable hospitals to precisely identify the infectious agent and any resistance to antibiotics. The company says its technology is based on semiconductor DNA sequencing, a specific type of next-generation sequencing that works by using a silicon chip to detect the ions released as a DNA strand is built up molecule by molecule.

---